Relmada Therapeutics Inc (RLMD)

Feb 25, 2025

Comprehensive Market Analysis of Latest Published Different Types of Depression Reports | DelveInsight - GlobeNewswire Inc.

Feb 25, 2025

Feb 24, 2025

RLMD stock touches 52-week low at $0.28 amid market challenges - Investing.com Australia

Feb 24, 2025

Feb 19, 2025

A significant driver of top-line growth: Relmada Therapeutics Inc (RLMD) - SETE News

Feb 19, 2025

Feb 16, 2025

Relmada acquires new Tourette syndrome treatment asset - MSN

Feb 16, 2025

Feb 11, 2025

Relmada Therapeutics Inc [RLMD] Investment Guide: What You Need to Know - Knox Daily

Feb 11, 2025

Feb 10, 2025

RLMD stock’s current quarter earnings estimates: What analysts predict? - US Post News

Feb 10, 2025

Feb 10, 2025

Closing Strong: Relmada Therapeutics Inc (RLMD) Ends at 0.31, Down -9.62 from Last Close - The Dwinnex

Feb 10, 2025

Feb 10, 2025

Relmada Therapeutics Inc’s Shares Reel: -90.69% Quarterly Revenue Decline Amid 9.33M Market Cap - The InvestChronicle

Feb 10, 2025

Feb 07, 2025

A company insider recently bought 51,407 shares of Relmada Therapeutics Inc [RLMD]. Should You Buy? - Knox Daily

Feb 07, 2025

Feb 07, 2025

Mizuho maintains Neutral on Relmada stock, sees deal potential - MSN

Feb 07, 2025

Feb 07, 2025

The Tourette’s Deal That Came Too Late To Save Sweden’s Asarina - News & Insights

Feb 07, 2025

Feb 07, 2025

Relmada in-licenses Tourette syndrome drug from Asarina - The Pharma Letter

Feb 07, 2025

Feb 07, 2025

Take off with Relmada Therapeutics Inc (RLMD): Get ready for trading - SETE News

Feb 07, 2025

Feb 07, 2025

Relmada acquires Tourette’s therapy rights from Asarina - Yahoo Finance

Feb 07, 2025

Feb 07, 2025

Lipella Pharmaceuticals Inc [LIPO] Revenue clocked in at $0.48 million, up 52.46% YTD: What’s Next? - The DBT News

Feb 07, 2025

Feb 07, 2025

Relmada acquires new Tourette syndrome treatment asset By Investing.com - Investing.com Nigeria

Feb 07, 2025

Feb 06, 2025

Mizuho maintains Neutral on Relmada stock, sees deal potential By Investing.com - Investing.com Australia

Feb 06, 2025

Feb 06, 2025

Relmada Therapeutics Acquires Sepranolone From Asarina Pharma For Potential TS Treatment - Nasdaq

Feb 06, 2025

Feb 06, 2025

Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB - Marketscreener.com

Feb 06, 2025

Feb 06, 2025

Relmada Therapeutics acquires Sepranolone from Asarina Pharma - TipRanks

Feb 06, 2025

Feb 06, 2025

Relmada Therapeutics (RLMD) Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB - StreetInsider.com

Feb 06, 2025

Feb 06, 2025

Groundbreaking Tourette Treatment Shows 69% QoL Improvement in Clinical TrialRelmada's Latest Acquisition - StockTitan

Feb 06, 2025

Feb 06, 2025

Relmada Therapeutics Acquires Sepranolone for CNS Portfolio - TipRanks

Feb 06, 2025

Feb 06, 2025

Relmada Therapeutics Inc (RLMD) Stock: Navigating a Year of Volatility - The InvestChronicle

Feb 06, 2025

Feb 06, 2025

Relmada Therapeutics Acquires Potential Therapy For Tourette Syndrome From Asarina Pharma AB - Marketscreener.com

Feb 06, 2025

Feb 04, 2025

A stock that deserves closer examination: Relmada Therapeutics Inc (RLMD) - US Post News

Feb 04, 2025

Feb 04, 2025

Relmada Therapeutics Inc (RLMD) may enjoy gains as insiders got busy in the recent days - Knox Daily

Feb 04, 2025

Feb 04, 2025

Investor’s Delight: Relmada Therapeutics Inc (RLMD) Closes Weak at 0.34, Down -2.61 - The Dwinnex

Feb 04, 2025

Feb 03, 2025

RLMD stock touches 52-week low at $0.34 amid sharp annual decline - Investing.com Canada

Feb 03, 2025

Feb 01, 2025

Relmada Therapeutics Inc (NASDAQ:RLMD) Has Made The 2.86% Recovery, Could Gain Another -1962.86% Ahead - Marketing Sentinel

Feb 01, 2025

Jan 29, 2025

Relmada Therapeutics (NASDAQ:RLMD) Receives Notification from Nasdaq Regarding Minimum Bid Price Compliance - Defense World

Jan 29, 2025

Jan 27, 2025

Relmada Therapeutics faces potential Nasdaq delisting - MSN

Jan 27, 2025

Jan 11, 2025

Geode Capital Management LLC Increases Stake in Relmada Therapeutics, Inc. (NASDAQ:RLMD) - Defense World

Jan 11, 2025

Jan 07, 2025

Relmada appoints new COO, freezes executive pay - Investing.com

Jan 07, 2025

Jan 07, 2025

Relmada appoints new COO, freezes executive pay By Investing.com - Investing.com UK

Jan 07, 2025

Jan 07, 2025

Relmada Therapeutics Appoints COO and Updates Executive CompensationRELMADA THERAPEUTICS, INC. (NASDAQ: RLMD) recently announced a significant update regarding its leadership team and executive compensation structure. According to a rec - Defense World

Jan 07, 2025

Jan 07, 2025

Relmada Therapeutics Strengthens Leadership with New COO - TipRanks

Jan 07, 2025

Jan 02, 2025

US Penny Stocks To Watch In January 2025 - Simply Wall St

Jan 02, 2025

Dec 20, 2024

RLMD stock touches 52-week low at $0.35 amid market challenges - Investing.com Canada

Dec 20, 2024

Dec 17, 2024

Relmada Therapeutics to Report Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 11, 2021 - BioSpace

Dec 17, 2024

Dec 13, 2024

Relmada stock hits 52-week low at $0.43 amid market challenges - Investing.com Australia

Dec 13, 2024

Dec 12, 2024

Relmada stock hits 52-week low at $0.43 amid market challenges By Investing.com - Investing.com South Africa

Dec 12, 2024

Dec 11, 2024

Relmada seeking strategic options, stock climbs 5% - MSN

Dec 11, 2024

Dec 11, 2024

Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm - The Eastern Progress Online

Dec 11, 2024